WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2001003719) COMBINATION THERAPY FOR CONDITIONS LEADING TO BONE LOSS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2001/003719 International Application No.: PCT/US2000/018667
Publication Date: 18.01.2001 International Filing Date: 07.07.2000
Chapter 2 Demand Filed: 08.02.2001
IPC:
A61K 38/17 (2006.01) ,A61K 38/55 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
55
Protease inhibitors
Applicants: AMGEN INC.[US/US]; One Amgen Center Drive Thousand Oaks, CA 91320-1799, US
Inventors: BOYLE, William, J.; US
LACEY, David, Lee; US
CALZONE, Frank, J.; US
CHANG, Ming-Shi; TW
SENALDI, Giorgio; US
Agent: ODRE, Steven, M. ; Amgen Inc. One Amgen Center Drive, 27-4-A Thousand Oaks, CA 91320-1799, US
Priority Data:
09/350,67009.07.1999US
09/457,64709.12.1999US
Title (EN) COMBINATION THERAPY FOR CONDITIONS LEADING TO BONE LOSS
(FR) POLYTHERAPIE DESTINEE A DES AFFECTIONS ENTRAINANT UNE PERTE OSSEUSE
Abstract:
(EN) The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis. Methods of treatment are described using the polypeptides in conjunction with various agents, including IL-1 inhibitors, TNF-$g(a) inhibitors, and serine protease inhibitors.
(FR) L'invention concerne un nouveau polypeptide sécrété, appelé ostéoprotégérine, qui fait partie de la superfamille des récepteurs du facteur de nécrose tumorale et qui joue un rôle dans la régulation du métabolisme osseux. L'invention concerne également des acides nucléiques codant pour l'ostéoprotégérine, des polypeptides, des vecteurs recombinants et des cellules hôtes d'expression, des anticorps qui se lient à l'ostéoprotégérine et des compositions pharmaceutiques. Lesdits polypeptides permettent de traiter des maladies osseuses caractérisées par une résorption accrue, tel que l'ostéoporose. L'invention concerne également des méthodes de traitement utilisant lesdits polypeptides conjointement avec différents agents, y compris les inhibiteurs de IL-1, les inhibiteurs de TNF-$g(a) et les inhibiteurs de la sérine-protéase.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)